Chapel Hill, NC, United States of America

Kenneth F Bastow

USPTO Granted Patents = 15 

Average Co-Inventor Count = 3.6

ph-index = 4

Forward Citations = 82(Granted Patents)


Company Filing History:


Years Active: 1995-2015

Loading Chart...
15 patents (USPTO):

Title: Innovations and Contributions of Kenneth F. Bastow

Introduction

Kenneth F. Bastow is a notable inventor based in Chapel Hill, NC (US), recognized for his significant contributions to the field of cancer treatment. With a total of 15 patents to his name, he has made remarkable strides in developing innovative compounds aimed at combating cancer.

Latest Patents

Among his latest patents are "Antofine and cryptopleurine derivatives as anticancer agents," which provides compounds of Formula (I-IV) and methods for their use in cancer treatment. Another significant patent is "Tylophorine analogs as antitumor agents," which describes compounds of Formula I and their pharmaceutical applications in treating cancer. These inventions highlight his commitment to advancing medical science and improving patient outcomes.

Career Highlights

Kenneth has worked at the University of North Carolina at Chapel Hill, where he has contributed to various research initiatives. His work has been instrumental in the development of new therapeutic agents that have the potential to change the landscape of cancer treatment.

Collaborations

Throughout his career, Kenneth has collaborated with esteemed colleagues such as Kuo-Hsiung Lee and Zhiyan Xiao. These partnerships have fostered a collaborative environment that enhances innovation and research in the field.

Conclusion

Kenneth F. Bastow's contributions to cancer research through his patents and collaborations underscore his role as a leading inventor in the medical field. His work continues to inspire advancements in cancer treatment and showcases the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…